Loading...
Images of Theresa Podrebarac
(0 from 0 )News
IL-23 Inhibitor Risankizumab Induces Remission in Phase II Study in...
news.abbvie.com
... with moderate-to-severe Crohn's disease who have failed anti-TNF therapy have very limited choices for treatment," said Theresa Podrebarac, vice president, ...
Biogen Idec to Highlight Innovative Pipeline and Commercial ...media.biogen.com › news-releases › news-release-details
media.biogen.com
... Theresa Podrebarac, MD, MSc, Vice President of Medical Research will provide a deeper dive into our early-stage immunology pipeline; and ...
Boehringer Ingelheim reveals promising results for Crohn's ...patientdaily.com › stories › boehringer-ing...
patientdaily.com
... therapy have very limited choices for treatment," Theresa Podrebarac, vice president of immunology clinical development for AbbVie, said.
ENGENE Press Release Archive - pre-IPO PHARMAwww.preipopharma.com › news-archive › engene
www.preipopharma.com
enGene announces appointment of Theresa Podrebarac, MD, as Chief Medical Officer. Apr 28, enGene's mucosal gene delivery platform is successful in ...
sorted by relevance / date